Adakveo

Chemical Namecrizanlizumab-tmca
Dosage FormInjectable (intravenous; 10 mg/mL)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyNovartis
Approval Year2019

Indication

  • Adakveo is indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Adakveo (crizanlizumab-tmca) Prescribing Information2019Novartis